Ascent Group LLC increased its position in Eli Lilly and Company shares by 3.3% during the third quarter, adding 575 shares to bring its total holdings to 17,821 shares. According to the firm’s latest 13F filing, this stake was valued at approximately $13.6 million as of the filing date, making Eli Lilly a meaningful component of Ascent’s broader pharmaceutical portfolio.

Generate Investment Management Ltd raised its Eli Lilly holdings to 81,813 shares in the third quarter, purchasing an additional 15,352 shares. This acquisition now represents roughly 3.2% of the firm’s total assets under management and ranks Eli Lilly as its seventh-largest individual equity holding, with a notional value of about $62.4 million at quarter end.

Calamos Advisors LLC reduced its Eli Lilly stake by 1.5% in the third quarter, selling 4,255 shares to end the period with 274,313 shares. Despite this modest reduction, the position remains Calamos’s 19th largest, representing nearly $209.3 million in market value, and reflecting a strategic reallocation within its health care sector exposure.

Overall institutional and hedge fund investors continue to hold 82.53% of Eli Lilly’s shares, underlining strong confidence from large-scale investors. Recent research reports by Wells Fargo, BMO Capital Markets and Truist Financial have collectively maintained or upgraded their ratings, with a consensus view of “Moderate Buy” and an average target price north of $1,150, indicating analysts’ expectations for continued earnings growth driven by the company’s GLP-1 franchise and pipeline developments.